IMPACT BIOMEDICAL INC.
IBO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IBO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IBO
Impact Biomedical Inc. (IBO) is a development-stage biopharmaceutical company focused on monetizing its existing technologies, with no current revenue and a history of relying on debt and related-party financing to fund operations.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials · 1 catalyst for IMPACT BIOMEDICAL INC..
Impact Biomedical Inc. (IBO) is a development-stage biopharmaceutical company focused on monetizing its existing technologies, with no current revenue and a history of relying on debt and related-party financing to fund operations.
- Impact Biomedical has no current revenue, reporting $0.0M in total revenue as of 2026-06-30 [sec].
- The company completed an initial public offering on September 16, 2024, raising $3,726,000 net of issuance costs and is listed on the NYSE American under ticker IBO [sec_mda · as of 2025-03-28].
- Shareholders' equity was $10.8M as of 2026-06-30 [sec].
- The company has historically met liquidity needs through debt financing and related-party support, with a revolving promissory note extended through September 30, 2030 [sec_mda · as of 2024-08-13].
- Management plans to continue as a going concern through monetization of intellectual property and tight cost controls [sec_mda · as of 2025-03-28].
What works
- The company completed an IPO in September 2024, raising net proceeds of $3.7M and gaining a public listing on NYSE American, providing a platform for future capital access [sec_mda · as of 2025-03-28].
- A related-party revolving promissory note extends through September 2030, offering a committed funding source from majority shareholder DSS, Inc. [sec_mda · as of 2024-08-13].
- Management is actively pursuing monetization of its intellectual property portfolio, which could generate future value without requiring additional R&D spending [sec_mda · as of 2025-03-28].
What to weigh
- The company has no revenue and reported a net loss of $0.7M for the period ending 2026-06-30, reflecting ongoing cash burn without product sales [sec].
- The company has a history of relying on debt and related-party financing, with cash as low as $2,000 as of June 30, 2024, indicating precarious liquidity [sec_mda · as of 2024-08-13].
- The company's ability to continue as a going concern depends on additional financing or successful monetization, which is uncertain [sec_mda · as of 2025-03-28].
- The company faces significant regulatory and clinical risks, including that drug candidates may not prove safe or efficacious, and FDA approval is uncertain [sec · filed 2023-10-17].
From the filings
Quoted directly from source documents.
The company completed an IPO in September 2024, raising $3.7M net.
“On September 16, 2024, the Company completed an initial public offering raising $3,726,000 net of issuance costs and is currently listed on the NYSE American under the ticker symbol IBO.”
SEC MD&A · March 28, 2025
The company had minimal cash as of June 30, 2024.
“As of June 30, 2024, the Company had cash of approximately $2,000.”
SEC MD&A · August 13, 2024
The company relies on a related-party note for liquidity.
“the Company has entered into an updated revolving promissory note which extended the maturity through September 30, 2030, and DSS, Inc. ("DSS"), the majority shareholder of the Company, intends to continue to fund the operations of the Company through a year from the date these financial statements were available to be issued.”
SEC MD&A · August 13, 2024
Catalyst timeline
- 2026-12-01 · Phase 2 Start — A Phase II, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of the company's lead candidate is scheduled to begin.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company's ability to continue as a going concern depends on additional financing or successful monetization of IP, which is not assured [sec_mda · as of 2025-03-28].
- No revenue or product sales — The company has zero revenue and relies on external funding, with no approved products generating income [sec].
- Clinical and regulatory risk — Drug candidates may fail to prove safe or efficacious, and FDA approval is costly, time-consuming, and uncertain [sec · filed 2023-10-17].
- Dependence on related-party financing — The company's liquidity is heavily dependent on continued support from majority shareholder DSS, Inc., which may not be sustained [sec_mda · as of 2024-08-13].
What to watch
- Initiation of the planned Phase II clinical trial for the company's lead candidate, expected to start around December 2026 [upcoming catalysts].
- Any updates on monetization of intellectual property, which management has identified as a key strategy [sec_mda · as of 2025-03-28].
- Changes in cash position and ability to secure additional financing, given the history of low cash reserves [sec_mda · as of 2024-08-13].
- Regulatory developments or FDA interactions regarding any drug candidates [sec · filed 2023-10-17].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run IMPACT BIOMEDICAL INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IMPACT BIOMEDICAL INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.25
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~93d
0 buys · 3 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$2.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,416,336 | $850K |
| geode capital management, llc | 1,192,925 | $716K |
| state street corp | 607,897 | $365K |
| vanguard fiduciary trust co | 585,198 | $351K |
| blackrock, inc. | 259,946 | $156K |
| northern trust corp | 243,943 | $146K |
| two sigma investments, lp | 37,427 | $22K |
| morgan stanley | 9,274 | $6K |
| global trust asset management, llc | 1,818 | $1K |
| citigroup inc | 353 | $212 |
Showing top 10 of 18 institutional holders of IMPACT BIOMEDICAL INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 16.3%
- Days to cover
- 0.2
- Shares short
- 1,915,023
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IBO short interestGovernance
Frequently asked questions
What is the AI investment thesis for IMPACT BIOMEDICAL INC.?
Impact Biomedical Inc. (IBO) is a development-stage biopharmaceutical company focused on monetizing its existing technologies, with no current revenue and a history of relying on debt and related-party financing to fund operations.
What is IMPACT BIOMEDICAL INC.'s next catalyst?
IMPACT BIOMEDICAL INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy an" — expected December 1, 2026.
Who is the CEO of IMPACT BIOMEDICAL INC.?
Mr. Frank D. Heuszel Esq., J.D. is the chief executive officer of IMPACT BIOMEDICAL INC. (IBO).
Where is IMPACT BIOMEDICAL INC. headquartered?
IMPACT BIOMEDICAL INC. (IBO) is headquartered in Houston, TX, United States.
What therapeutic areas does IMPACT BIOMEDICAL INC. focus on?
IMPACT BIOMEDICAL INC. develops therapies across Oncology, Neurology, Immunology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.